Hosted on MSN56m
Axsome Therapeutics Stock Tumbles As Alzheimer's Studies Reveal Mixed Results: Retail Sentiment Remains BullishShares of Axsome Therapeutics (AXSM) fell over 11% in Monday morning trade after it posted mixed results of its Alzheimer’s ...
Semorinemab is under clinical development by AC Immune and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition ...
Pepinemab is under clinical development by Vaccinex and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition ...
Dr Karan Rajan, an NHS surgeon and University of Sunderland lecturer, has shared his thoughts on 'menstrual blood-derived ...
Yoma was born Sept. 9, 1941 in Yonkers, NY, daughter of Yoma Elizabeth Hall (nee Woolcock) of Rangoon, Burma (now Yangon, ...
Caregivers in Arizona experience the heavy burden of Alzheimer's, with unpaid care valued at $10.2 billion annually.
The small miracles that 2024 brought to our lives lay the groundwork for new revolutionary treatments that are being prepared ...
Two scientists - Dr Zaldy Tan, a geriatric scientist, and Dr Glen Finney, a fellow of the American Academy of Neurology - ...
Investor's Business Daily on MSN3h
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's AgitationShares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.
The Alzheimer's Society says it is preparing for its busiest time of the year after families begin to notice signs of the ...
Axsome Therapeutics (AXSM) stock fell 12% Monday after the company reported mixed Phase 3 results for its drug AXS-05 in the ...
Researchers found that combining cardiovascular disease drug classes, particularly antihypertensives, can reduce risk of dementia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback